ACR score for rheumatoid arthritis
ANXA2
ARA-290
ATC code L01
ATC code L04
AZD-1480
Abatacept
Abemaciclib
Abetimus
Abrocitinib
Acalabrutinib
Adagrasib
Adalimumab
Adipotide
Afatinib
Afelimomab
Aflibercept
Agerafenib
Albinterferon
Alectinib
Alefacept
Alemtuzumab
Alpelisib
Amivantamab
Anakinra
Anaplastic lymphoma kinase
Anatomical Therapeutic Chemical Classification System
Anemia
Anifrolumab
Anti-lymphocyte globulin
Anti-thymocyte globulin
Antibody
Antifolate
Antimetabolite
Antineoplastic
Apremilast
Asciminib
Aselizumab
Asialo erythropoietin
Atezolizumab
Atezolizumab/hyaluronidase
Atiprimod
Atorolimumab
Aumolertinib
Avacopan
Avapritinib
Avelumab
Axatilimab
Axitinib
Azathioprine
BRAF (gene)
Baricitinib
Basigin
Basiliximab
Bcr-abl fusion protein
Begelomab
Belantamab mafodotin
Belatacept
Belgium
Belimumab
Bermekimab
Bertilimumab
Bevacizumab
Bifarcept
Bimekizumab
Binimetinib
Biological half-life
Blinatumomab
Blisibimod
Bosutinib
Brentuximab vedotin
Briakinumab
Brigatinib
Brodalumab
Bruton's tyrosine kinase
C-Met
CAS Registry Number
CD117
CD11a
CD135
CD154
CD18
CD20
CD23
CD30
CD33
CD3 (immunology)
CD4
CD40 (protein)
CD52
CD80
CDK inhibitor
CHZ868
CNTO-530
CTLA-4
CYP450
CYT387
Cabozantinib
Calcineurin
Canakinumab
Cancer immunotherapy
Capmatinib
Carbamylated erythropoietin
Carboxylesterase
Cardiotrophin 1
Catumaxomab
Cedelizumab
Cediranib
Cemiplimab
Cercosporamide
Ceritinib
Certolizumab pegol
Cetuximab
ChEMBL
ChemSpider
Chemical formula
Chemokine receptor
Chloramphenicol acetyltransferase
Ciclosporin
Cilmostim
Clenoliximab
ClinicalTrials.gov
Cobimetinib
Colony-stimulating factor receptor
Committee for Medicinal Products for Human Use
CompTox Chemicals Dashboard
Complement component 5
Copanlisib
Cosibelimab
Crizotinib
Crovalimab
Cucurbitacin I
Cyclophilin
Cytokine receptor
Cytokines
Dabrafenib
Daclizumab
Dacomitinib
Dalpiciclib
Danicopan
Daratumumab
Darbepoetin alfa
Darvadstrocel
Dasatinib
Decernotinib
Denileukin diftitox
Deucravacitinib
Deuruxolitinib
Dihydroorotate dehydrogenase
Dimethyl fumarate
Dinutuximab beta
Diroximel fumarate
Disease-modifying antirheumatic drug
Doi (identifier)
Dostarlimab
Double blind
DrugBank
Drug class
Drug nomenclature
Durvalumab
Duvelisib
EML4
Ecogramostim
Eculizumab
Edrecolomab
Efalizumab
Efgartigimod alfa
Efgartigimod alfa/hyaluronidase
Elotuzumab
Elranatamab
Elsilimomab
Eltrombopag
Emapalumab
Emfilermin
Encorafenib
Enfortumab vedotin
Entrectinib
EpCAM
Epcoritamab
Epidermal growth factor receptor
Epoetin alfa
Epoetin beta
Epoetin delta
Epoetin epsilon
Epoetin gamma
Epoetin kappa
Epoetin omega
Epoetin theta
Epoetin zeta
ErbB
Erdafitinib
Erlizumab
Erlotinib
Erythropoietin
Erythropoietin-Fc
Erythropoietin receptor
Etanercept
Etrasimod
European Medicines Agency
Everolimus
Exotoxin
FKBP
FMS-like tyrosine kinase 3 ligand
Faralimomab
Fedratinib
Fibroblast growth factor receptor
Filgotinib (data page)
Filgrastim
Fingolimod
Fontolizumab
Food and Drug Administration
Frexalimab
Fruquintinib
Fusion protein
Futibatinib
Galapagos NV
Galiximab
Gavilimomab
Gefitinib
Gemtuzumab ozogamicin
Gilead Sciences
Gilteritinib
Glasdegib
Glofitamab
Golimumab
Gomiliximab
Granulocyte-macrophage colony-stimulating factor
Granulocyte colony-stimulating factor
Granulocyte colony-stimulating factor receptor
Granulocyte macrophage colony-stimulating factor
Granulocyte macrophage colony-stimulating factor receptor
Guide to Pharmacology
Guselkumab
Gusperimus
HER2/neu
Hedgehog signaling pathway
IFNA10
IFNA13
IFNA14
IFNA16
IFNA17
IFNA2
IFNA21
IFNA4
IFNA5
IFNA6
IFNA7
IFNA8
IFNB1
IFNB3
IL-2 receptor
IUPAC nomenclature of chemistry
Ibritumomab tiuxetan
Ibrutinib
Icotinib
Idelalisib
Imatinib
Immunoglobulin E
Immunomodulatory imide drug
Immunosuppression
Immunosuppressive drug
Inavolisib
Indication (medicine)
Inebilizumab
Infigratinib
Inflammation
Infliximab
Inolimomab
Inotuzumab ozogamicin
Integrin
Interferon
Interferon-alpha/beta receptor
Interferon-gamma receptor
Interferon-lambda receptor
Interferon alfa
Interferon alfa 2a
Interferon alfa 2b
Interferon alfa n1
Interferon alfacon-1
Interferon alpha
Interferon alpha-n3
Interferon alpha 1
Interferon beta
Interferon beta 1a
Interferon beta 1b
Interferon gamma
Interferon gamma 1b
Interferon kappa
Interferon omega
Interferon receptor
Interleukin
Interleukin-34
Interleukin-6 receptor
Interleukin 12
Interleukin 13
Interleukin 17
Interleukin 1 receptor antagonist
Interleukin 2
Interleukin 23
Interleukin 5
Interleukin 6
Interleukin receptor
International Chemical Identifier
Ipilimumab
Iptacopan
Isatuximab
Itacitinib
Ixekizumab
JAK1
JAK2
JAK3
JSmol
Janus kinase
Janus kinase inhibitor
KEGG
KRAS
Keliximab
L-selectin
Lanimostim
Lapatinib
Larotrectinib
Lazertinib
Lebrikizumab
Leflunomide
Lenalidomide
Lenograstim
Lenvatinib
Lerdelimumab
Leridistim
Lestaurtinib
Leukemia
Leukemia inhibitory factor
Lipegfilgrastim
Loncastuximab tesirine
Lorlatinib
Lumiliximab
Lymphatic system
Lymphocyte function-associated antigen 1
Lymphoma
MEDI-545
MEN1
MTOR
MTOR inhibitor
Macrolide
Macrophage colony-stimulating factor
Macrophage colony-stimulating factor receptor
Masitinib
Maslimomab
Mavrilimumab
Mepolizumab
Metelimumab
Methotrexate
Methoxy polyethylene glycol-epoetin beta
Midostaurin
Milodistim
Mirimostim
Mirvetuximab soravtansine
Mitogen-activated protein kinase kinase
Mobocertinib
Mogamulizumab
Molar mass
Molgramostim
Momelotinib
Monoclonal antibody
Monoclonal antibody therapy
Morolimumab
Mosunetuzumab
Moxetumomab pasudotox
Muromonab-CD3
Mycophenolic acid
Myeloid
NSC-33994
NSC-7908
Namilumab
Nartograstim
Natalizumab
Naxitamab
Necitumumab
Neratinib
Nerelimomab
Netakimab
Netherlands
New Drug Application
Nilotinib
Nintedanib
Nivolumab
Non-receptor tyrosine kinase
Obinutuzumab
Oclacitinib
Ocrelizumab
Ocrelizumab/hyaluronidase
Odronextamab
Odulimomab
Ofatumumab
Olaratumab
Olmutinib
Olokizumab
Omalizumab
Oncostatin M
Opinercept
Oportuzumab monatox
Oral administration
Orelabrutinib
Osimertinib
Otelixizumab
Otilimab
Ozanimod
PDE4 inhibitor
PMC (identifier)
PMID (identifier)
Pacritinib
Palbociclib
Panitumumab
Parsaclisib
Pascolizumab
Pazopanib
Peficitinib
Pegacaristim
Pegcetacoplan
Pegfilgrastim
Peginesatide
Peginterferon alfa-2a
Peginterferon alfa-2b
Pegnartograstim
Pegol sihematide
Pembrolizumab
Pemigatinib
Pertuzumab
Pexelizumab
Pexidartinib
Pharmacokinetics
Phases of clinical research
Pi3K inhibitor
Pimecrolimus
Pirfenidone
Pirtobrutinib
Placebo-controlled
Platelet-derived growth factor receptor
Polatuzumab vedotin
Polyclonal antibodies
Pomalidomide
Ponatinib
Ponesimod
Pralsetinib
Prescription drug
Priority review
Proapoptotic
Prohibitin
Prolgolimab
Promegapoietin
Protein Data Bank
PubChem
Purine synthesis inhibitor
Quizartinib
RET proto-oncogene
RTK class III
Radotinib
Ramucirumab
Ravulizumab
Receptor modulator
Receptor tyrosine kinase
Regorafenib
Regramostim
Regulation of therapeutic goods
Repotrectinib
Reslizumab
Retifanlimab
Revumenib
Rheumatoid arthritis
Ribociclib
Ridaforolimus
Rilonacept
Ripretinib
Risankizumab
Ritlecitinib
Rituximab
Rociletinib
Romiplostim
Rontalizumab
Route of administration
Rovelizumab
Rozanolixizumab
Ruplizumab
Ruxolitinib
SD-1008
Sabatolimab
Sacituzumab govitecan
Sargramostim
Sarilumab
Satralizumab
Secukinumab
Selpercatinib
Selumetinib
Semaxanib
Serplulimab
Sifalimumab
Siltuximab
Simplified molecular-input line-entry system
Siplizumab
Siponimod